At three weeks post transplantation, marked GFP-labeled tumor masses were readily detectable in the brains transplanted with the control GFP but not ASCL1-infected U251 cells (data not shown), suggestive of the reduced tumorigenic activity of ASCL1-expressing human glioma cells in vivo. The gene discussed is ASCL1; the disease is glioma.